In vivo study, the subcutaneous tumor-forming assay was used in nude mice to detect the changes in the subcutaneous tumor-forming ability of HCC cells after NAT10 inhibition, and the changes in metastasis ability of HCC cells and the efficacy of lenvatinib after NAT10 downregulation. Here, NAT10 is linked to hepatocellular carcinoma.